Connor, Clark & Lunn Investment Management (CC&L)
TSVT

Connor, Clark & Lunn Investment Management (CC&L)’s 2seventy bio TSVT Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio TSVT Stock Details TSVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-11,071
Closed -$284K – 1217
2021
Q4 		$284K Buy
+11,071
New +$345K ﹤0.01% 901

Other funds holding TSVT

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s TSVT Position: Q1 2022 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of 2seventy bio (TSVT) in Q1 2022, closing a stake of 11,071 shares — an estimated $284K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in TSVT in Q4 2021 and held it in 1 quarter. The position peaked at $284K in Q4 2021. 134 funds tracked by Wall St. Rank hold TSVT as of Q1 2022.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining 2seventy bio position as of Q1 2022 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 11,071 2seventy bio shares in Q1 2022, an estimated $284K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in 2seventy bio in Q4 2021 and held it in 1 quarter.
  • Connor, Clark & Lunn Investment Management (CC&L)'s 2seventy bio position peaked at $284K in Q4 2021.
  • 134 funds tracked by Wall St. Rank held 2seventy bio as of Q1 2022.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2022, filed 12 May 2022.